Human herpesviruses 6, 7 and 8 in solid organ transplant recipients

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1% of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most commonmanifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV- 6 and HHV-7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV-8 is an oncogenic gamma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV- 8. Reduction in immunosuppression is the first line treatment of HHV-8 infection. Other alternatives for treatment, especially for HHV-8 diseases not responsive to immuno-minimization strategies, are surgery and chemotherapy. Sirolimus has been shown to be a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV-8 infection is being investigated.

Original languageEnglish (US)
Pages (from-to)67-78
Number of pages12
JournalAmerican Journal of Transplantation
Volume13
Issue numberSUPPL. 3
DOIs
StatePublished - 2013

Fingerprint

Human Herpesvirus 7
Human Herpesvirus 6
Human Herpesvirus 8
Transplants
Herpesviridae Infections
Kaposi's Sarcoma
Immunosuppression
Antiviral Agents
Bone Marrow
Primary Effusion Lymphoma
Giant Lymph Node Hyperplasia
Therapeutics
Herpesviridae
Sirolimus
Exanthema
Fever
Transplant Recipients
Viruses
Drug Therapy
Infection

Keywords

  • Human herpesvirus 6
  • Human herpesvirus 7
  • Human herpesvirus 8
  • Kaposi's sarcoma
  • Roseola infantum

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. / Razonable, Raymund R.

In: American Journal of Transplantation, Vol. 13, No. SUPPL. 3, 2013, p. 67-78.

Research output: Contribution to journalArticle

@article{43313860fb144c4ab9fde6ca93f467ca,
title = "Human herpesviruses 6, 7 and 8 in solid organ transplant recipients",
abstract = "Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1{\%} of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most commonmanifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV- 6 and HHV-7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV-8 is an oncogenic gamma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV- 8. Reduction in immunosuppression is the first line treatment of HHV-8 infection. Other alternatives for treatment, especially for HHV-8 diseases not responsive to immuno-minimization strategies, are surgery and chemotherapy. Sirolimus has been shown to be a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV-8 infection is being investigated.",
keywords = "Human herpesvirus 6, Human herpesvirus 7, Human herpesvirus 8, Kaposi's sarcoma, Roseola infantum",
author = "Razonable, {Raymund R}",
year = "2013",
doi = "10.1111/ajt.12008",
language = "English (US)",
volume = "13",
pages = "67--78",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Human herpesviruses 6, 7 and 8 in solid organ transplant recipients

AU - Razonable, Raymund R

PY - 2013

Y1 - 2013

N2 - Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1% of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most commonmanifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV- 6 and HHV-7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV-8 is an oncogenic gamma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV- 8. Reduction in immunosuppression is the first line treatment of HHV-8 infection. Other alternatives for treatment, especially for HHV-8 diseases not responsive to immuno-minimization strategies, are surgery and chemotherapy. Sirolimus has been shown to be a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV-8 infection is being investigated.

AB - Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1% of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most commonmanifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV- 6 and HHV-7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV-8 is an oncogenic gamma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV- 8. Reduction in immunosuppression is the first line treatment of HHV-8 infection. Other alternatives for treatment, especially for HHV-8 diseases not responsive to immuno-minimization strategies, are surgery and chemotherapy. Sirolimus has been shown to be a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV-8 infection is being investigated.

KW - Human herpesvirus 6

KW - Human herpesvirus 7

KW - Human herpesvirus 8

KW - Kaposi's sarcoma

KW - Roseola infantum

UR - http://www.scopus.com/inward/record.url?scp=84879928439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879928439&partnerID=8YFLogxK

U2 - 10.1111/ajt.12008

DO - 10.1111/ajt.12008

M3 - Article

C2 - 23347215

AN - SCOPUS:84879928439

VL - 13

SP - 67

EP - 78

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - SUPPL. 3

ER -